



I. Epidemiological profile

Population (UN Population Division)	2012	%
High transmission (>1 case per 1000 population)	0	0
Low transmission (0–1 cases per 1000 population)	430 000	50
Malaria-free (0 cases)	430 000	50
Total	860 000	

Parasites and vectors	
Major plasmodium species:	<i>P. falciparum</i> (100%), <i>P. vivax</i> (0%)
Major anopheles species:	<i>An. gambiae</i> , <i>arabiensis</i>
Programme phase: Control	

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2008
	ITNs/LLINs distributed to all age groups	No	–
IRS	IRS is recommended	Yes	2006
	DDT is used for IRS	No	–
Larval control	Use of larval control	Yes	–
IPT	IPT used to prevent malaria during pregnancy	N/A	–
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2007
	Malaria diagnosis is free of charge in the public sector	Yes	2007
Treatment	ACT is free for all ages in public sector	Yes	2007
	Artemisinin-based monotherapies withdrawn	Yes	–
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for <i>P. falciparum</i>	No	–
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	–
	G6PD test is a requirement before treatment with primaquine	No	–
	Directly observed treatment with primaquine is undertaken	No	–
	System for monitoring of adverse reaction to antimalarials exists	No	–



Intervention	Policies/strategies	Yes/No	Year adopted
Surveillance	ACD for case investigation (reactive)	No	–
	ACD at community level of febrile cases (pro-active)	No	–
	Mass screening is undertaken	No	–
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	–
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	–

Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	AL	2013
First-line treatment of <i>P. falciparum</i>	AL	2013
For treatment failure of <i>P. falciparum</i>	AL	2008
Treatment of severe malaria	QN	–
Treatment of <i>P. vivax</i>	–	–
Dosage of primaquine for radical treatment of <i>P. vivax</i>	–	–



Type of RDT used	<i>Pf</i> only
Therapeutic efficacy tests (clinical and parasitological failure, %)	

Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
----------	------	-----	--------	-----	-----------	----------------	---------





III. Financing



IV. Coverage



V. Impact



Impact: Insufficiently consistent data to assess trends